Ceftazidimeavibactam use in children and adolescents | CMAC

Ceftazidimeavibactam use in children and adolescents

Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(2):173-183

​ Stetsiouk О.U., Andreeva I.V., Lekmanov А.U., Haykina Е.V.
10.36488/cmac.2021.2.173-183
ceftazidime-avibactam children complicated intra-abdominal infections complicated urinary tract infections nosocomial pneumonia multidrug-resistant Gram-negative bacteria
Section
Antimicrobials
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(2):173-183

Abstract

The increasing number of infections caused by multidrug-resistant gram-negative bacteria in children is a serious problem all over the world. Ceftazidim-avibactam is a promising antimicrobial drug recently approved in Russia for use in pediatric practice. This review provides information on the possible use of ceftazidime-avibactam in children with complicated intraabdominal infections (in combination with metronidazole); complicated urinary tract infections, including pyelonephritis; hospital-acquired pneumonia, including ventilator-associated pneumonia; infections caused by aerobic gram-negative microorganisms in patients with limited choice of antibacterial therapy. Based on the data on the in vitro activity of the drug, the results of clinical studies of pharmacokinetics, safety and efficacy of ceftazidimeavibactam for the treatment of infections in children the main clinical cases in which the use of ceftazidimeavibactam in pediatric practice is most justified and appropriate are identified.

Stetsiouk О.U.

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Irina V. Andreeva

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Lekmanov А.U.

Pirogov Russian National Research Medical University, Moscow, Russia

Haykina Е.V.

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. Meropol S.B., Haupt A.A., Debanne S.M. Incidence and outcomes of infections caused by multidrug-resistant Enterobacteriaceae in children, 2007-2015. J Pediatric Infect Dis Soc. 2018;7(1):36-45. DOI: 10.1093/jpids/piw093
  • 2. Resolution of the Expert Council Principles of rational antibiotic therapy for respiratory infections in children. We will preserve antibiotics for future generations. March 31, 2018, Moscow. Pediatrics. 2018;3:10-15. Russian. DOI: 10.26442/2413-8460_2018.3.10-15
  • 3. Kozlov R.S., Stetsiouk O.U., Andreeva I.V. Current trends in antibiotic resistance of nosocomial infection pathogens in the Russian ICU: what's coming next? Intensivnaja terapija. 2007;4:217-227. Russian.
  • 4. Namazova-Baranova L.S., Baranov A.A. Antibiotic resistance in the modern world. Pediatricheskaja farmakologija. 2017;14(5):341-354. Russian. DOI: 10.15690/pf.v14i5.1782
  • 5. Ilyina S.V. Misuse of antibiotics in medicine: the crisis of antibiotic resistance and what we can do. Pediatricheskaja farmakologija. 2017;14(6):508-514. Russian. DOI: 10.15690/pf.v14i6.1834
  • 6. Stetsiouk O.U., Andreeva I.V. Modern principles of antibacterial therapy of severe and life-threatening bacterial infections. Farmateka. 2008;4:12-17. Russian.
  • 7. Sukhorukova M.V., Eidelstein M.V., Skleenova E.Yu., Ivanchik N.V., Mikotina A.V., Dekhnich A.V., et al. Antibiotic resistance of nosocomial strains of Enterobacteriaceae in hospitals in Russia: results of a multicenter epidemiological study MARATHON 2013-2014. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(1):49-56. Russian.
  • 8. Eidelstein M.V., Sukhorukova M.V., Skleenova E.Yu., IvanchikN.V., Mikotina A.V., Shek E.A., et al. Antibiotic resistance of nosocomial strains of Pseudomonas aeruginosa in hospitals in Russia: results of the multicenter epidemiological study MARATHON 2013-2014. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(1):37-41. Russian.
  • 9. Eidelstein M.V., Sukhorukova M.V., Skleenova E.Yu., Ivanchik N.V., Mikotina A.V., Shek E.A., et al. Antibiotic resistance of nosocomial strains of Pseudomonas aeruginosa in hospitals in Russia: results of the multicenter epidemiological study MARATHON 20132014. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(1):37-41. Russian.
  • 10. Shaidullina E.R., Eidelstein M.V., Skleenova E.Yu., Sukhorukova M.V., Kozlov R.S. Antibiotic resistance of nosocomial carbapenemase-producing strains of Enterobacterales in Russia: results of an epidemiological study in 2014-2016. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2018;20(4):362-369. Russian. DOI: 10.36488/cmac.2018.4.362-369
  • 11. Sukhorukova M.V., Eidelstein M.V., Ivanchik N.V., Skleenova E.Yu., Shaidullina E.R., Shek E.A., et al. Antibiotic resistance of nosocomial strains of Enterobacterales in hospitals in Russia: results of multicenter epidemiological study MARATHON 20152016. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2019;21(2):147-159. Russian. DOI: 10.36488/cmac.2019.2.147-159
  • 12. Shek E.A., Sukhorukova M.V., Eidelstein M.V., Skleenova ­E.Yu., Ivanchik N.V., Shaydullina E.R., et al. Antibiotic resistance, carbapenemase production and genotypes of nosocomial Pseudomonas aeruginosa strains in Russian hospitals: results of the multicenter epidemiological study MARATHON 2015-2016. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2019;21(2):160-170. Russian. DOI: 10.36488/cmac.2019.2.160-170
  • 13. Shek E.A., Sukhorukova M.V., Eidelstein M.V., Skleenova E.Yu., Ivanchik N.V., Shaydullina E.R., et al. Antibiotic resistance, carbapenemase production and genotypes of nosocomial strains of Acinetobacter spp. in hospitals in Russia: results of the multicenter epidemiological study MARATHON 2015-2016. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2019;21(2):171-180. Russian. DOI: 10.36488/cmac.2019.2.171-18
  • 14. Kuzmenkov A.Yu., Trushin I.V., Avramenko A.A., Edelstein M.V., Dekhnich A.V., Kozlov R.S. AMRmap: an online platform for monitoring antibiotic resistance. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(2):84-90. Russian.
  • 15. Instructions for use of the medicinal product for medical use Zavicefta® LP-004289-020421. Available at: https://grls.rosminzdrav.ru. Russian.
  • 16. Kozlov R.S., Stetsiouk O.U., Andreeva I.V. Ceftazidimeavibactam: new “rules of the game” against multidrugresistant gram-negative bacteria. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2018;20(1):24-34. Russian. DOI: 10.36488/cmac.2018.1.24-34
  • 17. Flokas M.E., Detsis M., Alevizakos M., Mylonakis E. Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: A systematic review and meta-analysis. J Infect. 2016;73(6):547-557. DOI: 10.1016/j.jinf.2016.07.014
  • 18. Sader H.S., Huband M.D., Duncan L.R., Flamm R.K. Ceftazidime-avibactam antimicrobial activity and spectrum when tested against Gram-negative organisms from pediatric patients: Results from the INFORM Surveillance Program (United States, 2011-2015). Pediatr Infect Dis J. 2018;37(6):549-554. DOI: 10.1097/INF.0000000000001859
  • 19. Bradley J.S., Armstrong J., Arrieta A., Bishai R., Das S., Delair S., et al. Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients. Antimicrob Agents Chemother. 2016;60(10):6252-6259. DOI: 10.1128/AAC.00862-16
  • 20. Bradley J.S., Broadhurst H., Cheng K., Mendez M., Newell P., Prchlik M., et al. Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children ≥3 months to <18 years with complicated intraabdominal infection: results from a Phase 2, randomized, controlled trial. Pediatr Infect Dis J. 2019;38(8):816-824. DOI: 10.1097/INF.0000000000002392
  • 21. Bradley J.S., Roilides E., Broadhurst H., Cheng K., Huang L.M., MasCasullo V., et al. Safety and efficacy of ceftazidime-avibactam in the treatment of children ≥3 months to <18 years with complicated urinary tract infection: results from a Phase 2 randomized, controlled trial. Pediatr Infect Dis J. 2019;38(9):920-928. DOI: 10.1097/INF.0000000000002395
  • 22. U.S. National Library of Medicine. ClinicalTrials.gov. Available at: www.clinicaltrials.gov/ct2/results?cond=&term=ceftazidim+AND+avibactam. Accessed on 29.01.2021.
  • 23. Schwartz G.J., Work D.F. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4(11):1832-1843. DOI: 10.2215/CJN.01640309
  • 24. Iosifidis E., Chorafa E., Agakidou E., Kontou A., Violaki A., Volakli E., et al. Use of ceftazidime-avibactam for the treatment of extensively drug-resistant or pan drug-resistant Klebsiella pneumoniae in neonates and children <5 years of age. Pediatr Infect Dis J. 2019;38(8):812-815. DOI: 10.1097/INF.0000000000002344
  • 25. Algwizani A., Alzunitan M., Alharbi A., Alsaedy A., Aljohani S., Alalwan B., et al. Experience with ceftazidimeavibactam treatment in a tertiary care center in Saudi Arabia. J Infect Public Health. 2018;11(6):793-795. DOI: 10.1016/j.jiph.2018.04.013
  • 26. Papp-Wallace K.M., Becka S.A., Zeiser E.T., Ohuchi N., Mojica M.F., Gatta J., et al. Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients. ACS Infect Dis. 2017;3(7):502511. DOI: 10.1021/acsinfecdis.7b00020
  • 27. Tamma P.D., Fan Y., Bergman Y., Sick-Samuels A.C., Hsu A.J., Timp W., et al. Successful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime-avibactam. Antimicrob Agents Chemother. 2018;62(4):e02213-17. DOI: 10.1128/AAC.02213-17
  • 28. Nguyen T.T., Condren M., Walter J. Ceftazidime-avibactam for the treatment of multidrug resistant Burkholderia cepacia complex in a pediatric cystic fibrosis patient. Pediatr Pulmonol. 2020;55(2):283-284. DOI: 10.1002/ppul.24557
  • 29. Marshall S., Hujer A.M., Rojas L.J., Papp-Wallace K.M., Humphries R.M., Spellberg B., et al. Can ceftazidimeavibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017;61(4):e02243-16. DOI: 10.1128/AAC.02243-16
  • 30. Wenzler E., Deraedt M.F., Harrington A.T., Danizger L.H. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamaseproducing gram-negative pathogens. Diagn Microbiol Infect Dis. 2017;88(4):352-354. DOI: 10.1016/j.diagmicrobio.2017.05.009
  • 31. Davido B., Fellous L., Lawrence C., Maxime V., Rottman M., Dinh A. Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61(9):e01008-17. DOI: 10.1128/AAC.01008-17
  • 32. Pragasam A.K., Veeraraghavan B., Shankar B.A., Bakthavatchalam Y.D., Mathuram A., George B., et al. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-like producing organisms: lessons learnt from in vitro study. Indian J Med Microbiol. 2019;37(1):3441. DOI: 10.4103/ijmm.IJMM_19_189
  • 33. Hobson C.A., Bonacorsi S., Fahd M., Baruchel A., Cointe A., Poey N., et al. Successful treatment of bacteremia due to NDM-1-producing Morganella morganii with aztreonam and ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy. Antimicrob Agents Chemother. 2019;63(2):e02463-18. DOI: 10.1128/AAC.02463-18
  • 34. Rup A.R., Dash A.K., Patnaik S. Ceftazidime-avibactam for hospital acquired pneumonia due to extended drugresistant Klebsiella pneumoniae. Indian J Pediatr. 2020; 1-2. DOI: 10.1007/s12098-020-03546-y
Views
0 Abstract
0 PDF
0 Crossref citations
Shared